glp-1 therapy weight loss milestones timeline receptor agonism: a transformative approach for managing type-2 diabetes and obesity | Saudi Pharmaceutical Journal What are GLP-1s? | Mendinground

& Hoffman, A

Important Note : If you have heart failure, chronic kidney disease, or liver disease, follow your healthcare provider's specific guidance on fluid intake, as these conditions may require fluid restriction rather than increased consumption

To address these concerns, future research should prioritize large-scale, longitudinal studies evaluating the long-term cardiovascular impacts of IF, particularly in vulnerable populations such as the elderly or those with preexisting cardiovascular conditions

OCallaghan-Gordo C, Shivashankar R, Anand S, Ghosh S, Glaser J, Gupta R, et al

Minimizing food noise Social worker and elder care consultant Bethany J